Ribavirin for treating Crimean Congo hemorrhagic fever -- latest Cochrane review

(Liverpool School of Tropical Medicine) In a viral hemorrhagic disease where up to 40 percent of people developing it die, it is remarkable that doctors still do not agree whether the only recognized treatment, an antiviral drug called ribavirin, makes a difference. In a new Cochrane Review a team of authors at LSTM, along with colleagues in London, the Philippines and in Greece, evaluated the evidence to assess the effectiveness of treating Crimean Congo hemorrhagic fever (CCHF).
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news